|
Forecast
Period
|
2025-2029
|
|
Market
Size (2023)
|
USD
2.67 Billion
|
|
Market
Size (2029)
|
USD
3.82 Billion
|
|
CAGR
(2024-2029)
|
6.13%
|
|
Fastest
Growing Segment
|
Nanopore
Sequencing
|
|
Largest
Market
|
North
America
|
Market Overview
Global
NGS-Based RNA-Sequencing Market was valued at USD 2.67 billion in 2023 and will
see an impressive growth in the forecast period at a CAGR of 6.13% through 2029. Next-Generation Sequencing (NGS)-Based
RNA-Sequencing, often abbreviated as RNA-Seq, is a powerful technique used to
analyze the transcriptome, which refers to the complete set of RNA molecules in
a cell or tissue at a specific time point. RNA-Seq allows researchers to
investigate gene expression levels, alternative splicing patterns, RNA modifications,
and other transcriptomic features with high throughput and resolution. The RNA molecules of interest are
extracted from cells or tissues using specialized protocols that preserve RNA
integrity and minimize degradation. Total RNA, which includes messenger RNA
(mRNA), non-coding RNA (e.g., microRNA, long non-coding RNA), and ribosomal RNA
(rRNA), is isolated and purified from the sample. The isolated RNA molecules
are converted into a sequencing library through a series of enzymatic
reactions. During library preparation, the RNA is fragmented into smaller
pieces, reverse transcribed into complementary DNA (cDNA) using reverse
transcriptase enzymes, and adapters are ligated to the cDNA fragments to enable
sequencing. Various library preparation kits and protocols are available to
accommodate different RNA-Seq applications, such as stranded RNA-Seq,
poly(A)-enriched RNA-Seq, and total RNA-Seq. The prepared RNA-Seq libraries are sequenced using
high-throughput NGS platforms, such as Illumina, Ion Torrent, or PacBio
sequencers. During sequencing, fluorescently labeled nucleotides are
incorporated into complementary strands of DNA or RNA molecules, generating
millions to billions of short sequencings reads in a massively parallel
fashion.
Continuous
advancements in next-generation sequencing (NGS) technologies have
significantly improved the speed, accuracy, and cost-effectiveness of RNA
sequencing. Innovations such as long-read sequencing, single-cell RNA
sequencing, and real-time sequencing capabilities have expanded the
applications and accessibility of RNA sequencing, driving market growth. The
growing interest and investment in genomic research, particularly in areas such
as transcriptomics and functional genomics, fuel the demand for RNA sequencing
technologies. Researchers across various fields, including molecular biology,
medicine, agriculture, and biotechnology, rely on RNA sequencing to investigate
gene expression, splicing variants, RNA modifications, and regulatory networks.
RNA sequencing is increasingly utilized for clinical diagnostics, particularly
in oncology and rare diseases. The ability to detect gene fusions, mutations,
and expression patterns using RNA sequencing aids in cancer diagnosis,
prognosis, and treatment selection. Additionally, RNA sequencing facilitates
the identification of causative genetic variants in rare and undiagnosed
diseases, driving its integration into clinical practice and molecular
pathology.
Key Market Drivers
Advancements in Sequencing
Technologies
NGS
technologies represent a paradigm shift in DNA sequencing, allowing for
high-throughput sequencing of DNA and RNA molecules. NGS platforms, such as
Illumina's sequencing systems, enable researchers to sequence millions of DNA
fragments or RNA transcripts in parallel, significantly increasing sequencing
speed and throughput compared to traditional Sanger sequencing methods. Single-cell
sequencing technologies enable the profiling of individual cells' genomes,
transcriptomes, and epigenomes with high resolution. These technologies,
including single-cell RNA sequencing (scRNA-seq), single-cell DNA sequencing
(scDNA-seq), and single-cell ATAC-seq (scATAC-seq), provide insights into
cellular heterogeneity, developmental processes, and disease mechanisms at the single-cell
level. Long-read sequencing technologies, such as those offered by Pacific
Biosciences (PacBio) and Oxford Nanopore Technologies, generate sequencing
reads that span thousands to tens of thousands of base pairs. Long-read
sequencing facilitates the detection of structural variations, complex genomic
rearrangements, and full-length transcripts, overcoming limitations associated
with short-read sequencing technologies.
Real-time
sequencing platforms, such as nanopore sequencing by Oxford Nanopore
Technologies, enable the direct, label-free detection of nucleic acids as they
pass through nanopores. Real-time sequencing provides rapid turnaround times,
enables dynamic monitoring of biological processes, and supports applications
such as pathogen detection, environmental surveillance, and RNA transcript
analysis. Epigenetic sequencing technologies, including DNA methylation
sequencing (e.g., bisulfite sequencing) and chromatin immunoprecipitation
sequencing (ChIP-seq), allow researchers to study epigenetic modifications and
chromatin dynamics at genome-wide scales. These technologies provide insights
into gene regulation, cell differentiation, and disease mechanisms by profiling
DNA methylation patterns, histone modifications, and transcription factor
binding sites. Metagenomic sequencing enables the comprehensive analysis of
microbial communities and environmental samples without the need for
culture-based methods. Metagenomic sequencing technologies, such as shotgun
metagenomics and 16S rRNA gene sequencing, facilitate the identification of
microbial species, functional gene annotation, and microbiome characterization
in diverse habitats, including the human gut, soil, water, and air. This factor
will help in the development of the Global NGS-Based RNA-Sequencing Market.
Rapid Growth of Genomic
Research
Genomic
research encompasses a wide range of applications, including transcriptomics,
epigenomics, metagenomics, and comparative genomics. RNA sequencing,
specifically, provides insights into gene expression patterns, alternative
splicing events, RNA modifications, and regulatory networks. Researchers
leverage RNA sequencing data to study development, disease mechanisms, drug
responses, and evolutionary relationships across diverse biological systems. Advances
in NGS technologies have democratized genomic research by enabling
high-throughput sequencing of DNA and RNA molecules at unprecedented speed and
scale. NGS platforms, such as Illumina's sequencing systems and those offered
by other manufacturers, facilitate the generation of large volumes of sequencing
data with high accuracy and resolution. These technological advancements have
expanded the accessibility of RNA sequencing to researchers in academia,
industry, and clinical settings. The decreasing costs of sequencing
technologies and associated reagents have made RNA sequencing more affordable
and accessible to research laboratories worldwide. As the price per base pair
continues to decline, researchers can conduct large-scale RNA sequencing
experiments, population-based studies, and longitudinal analyses without
significant financial constraints. The affordability of RNA sequencing drives
its widespread adoption across diverse research disciplines and institutions.
Genomic
research increasingly integrates RNA sequencing with other omics technologies,
such as DNA sequencing, epigenetic profiling, proteomics, and metabolomics.
Multi-omics approaches enable comprehensive molecular profiling and
systems-level analysis of biological systems, providing a holistic view of gene
regulation, signaling pathways, and cellular interactions. RNA sequencing data
complement other omics datasets, enhancing our understanding of complex
biological processes and disease phenotypes. Genomic research findings have
translational implications for healthcare, agriculture, environmental science,
and biotechnology. RNA sequencing technologies play a crucial role in
translational research and clinical applications, including biomarker discovery,
diagnostic assay development, patient stratification, and treatment
optimization. RNA sequencing data informs precision medicine approaches,
facilitates the identification of therapeutic targets, and support
evidence-based decision-making in clinical practice. This factor will pace up
the demand of the Global NGS-Based RNA-Sequencing Market.
Expanding Applications in
Clinical Diagnostics
NGS-based
RNA sequencing enables precise molecular characterization of diseases, aiding
in the development of personalized treatment strategies. By profiling RNA
expression patterns, identifying genetic mutations, and detecting fusion genes,
RNA sequencing helps clinicians tailor therapies to individual patients based
on their unique genetic profiles. RNA sequencing is instrumental in cancer
diagnostics and prognostics. It allows for the identification of gene
expression signatures associated with different cancer types, tumor subtypes,
and disease progression stages. RNA sequencing can detect driver mutations,
predict treatment responses, monitor minimal residual disease, and identify
drug resistance mechanisms, guiding clinical decision-making in oncology. NGS-based
RNA sequencing facilitates the diagnosis of rare and undiagnosed diseases by
identifying causative genetic variants, including point mutations,
insertions/deletions, and copy number variations. RNA sequencing can uncover
pathogenic mutations affecting gene expression, splicing, and regulatory
elements, providing insights into disease mechanisms, and informing genetic
counseling and family planning. RNA sequencing is increasingly used in the
diagnosis and surveillance of infectious diseases, including viral infections,
bacterial pathogens, and fungal pathogens. RNA sequencing can detect microbial
RNA transcripts, viral RNA genomes, and host immune responses, enabling the
rapid identification and characterization of infectious agents, monitoring of
disease outbreaks, and assessment of antimicrobial resistance patterns.
RNA
sequencing plays a crucial role in pharmacogenomics by identifying genetic
variants associated with drug metabolism, drug efficacy, and adverse drug
reactions. RNA sequencing data can predict individual responses to
pharmacotherapy, optimize drug dosing regimens, and minimize adverse drug
events, enhancing patient safety and treatment outcomes in clinical practice. RNA sequencing is utilized in non-invasive
prenatal testing to detect fetal chromosomal abnormalities, such as trisomy 21
(Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau
syndrome). RNA sequencing of cell-free fetal RNA in maternal blood enables
early detection of genetic disorders, reducing the need for invasive procedures
like amniocentesis and chorionic villus sampling. RNA sequencing enables the
analysis of circulating RNA biomarkers in blood, urine, and other body fluids
for cancer detection, monitoring treatment response, and assessing disease
recurrence. Liquid biopsy-based RNA sequencing offers a minimally invasive
alternative to tissue biopsies and facilitates real-time monitoring of disease
dynamics and therapeutic interventions. This factor will accelerate the demand
of the Global NGS-Based RNA-Sequencing Market.
Download Free Sample Report
Key Market Challenges
Data Analysis and
Interpretation Complexity
RNA-sequencing
generates massive amounts of raw sequencing data that require sophisticated
bioinformatics tools and computational expertise for analysis and
interpretation. Analyzing transcriptomic data involves multiple steps,
including quality control, read alignment, transcript quantification,
differential gene expression analysis, pathway analysis, and functional
annotation. Researchers often need specialized training in bioinformatics and
computational biology to effectively analyze RNA-sequencing data and extract
meaningful biological insights. There is a lack of standardized data analysis
pipelines for RNA-sequencing data, leading to variability in analysis
methodologies and results across different studies and laboratories.
Researchers may use different software tools, algorithms, and parameters for
data processing and analysis, which can impact the reproducibility and
comparability of results. Establishing consensus guidelines and best practices
for RNA-sequencing data analysis is essential for promoting consistency and
transparency in research findings. RNA-sequencing data are inherently complex,
reflecting the dynamic nature of gene expression and alternative splicing
events across different biological conditions and cell types. Analyzing
transcriptomic data requires accounting for various sources of variability,
including technical noise, biological heterogeneity, and experimental
confounders. Moreover, identifying biologically relevant signals amidst
background noise and false positives poses challenges for data interpretation
and validation.
Integrating
RNA-sequencing data with other omics data types, such as genomics, proteomics,
and metabolomics, adds another layer of complexity to data analysis and
interpretation. Integrated multi-omics analyses enable researchers to gain a
more comprehensive understanding of biological systems and disease mechanisms.
However, integrating heterogeneous data sets from different experimental
platforms and data sources requires specialized computational methods and tools
for data integration, normalization, and statistical analysis. Ensuring the
reproducibility and reliability of RNA-sequencing results is a critical concern
in the field. Researchers must implement rigorous quality control measures
throughout the experimental workflow to minimize technical artifacts, batch
effects, and systematic biases that can confound data analysis and
interpretation. Standardizing quality control metrics and reporting guidelines
for RNA-sequencing experiments can help improve data reproducibility and
facilitate data sharing and meta-analysis efforts.
Sample Heterogeneity and
Complexity
Biological
samples, particularly tissues and organs, consist of diverse cell populations
with distinct gene expression profiles. Studying heterogeneous samples using
RNA-sequencing requires methods to capture and analyze gene expression patterns
at the single-cell or subpopulation level. Bulk RNA-sequencing may mask
cell-specific gene expression signatures, leading to a loss of resolution and
biological insights. Tumors are characterized by intratumoral heterogeneity,
where different regions of the tumor exhibit distinct molecular profiles and
cellular phenotypes. RNA-sequencing studies of tumors must account for spatial
and temporal variations in gene expression, as well as the presence of rare
cell populations, tumor subclones, and microenvironmental factors.
Understanding tumor heterogeneity is critical for identifying therapeutic
targets, predicting treatment response, and monitoring disease progression.
Biological
systems exhibit dynamic changes in gene expression over time in response to
developmental cues, environmental stimuli, and disease processes. Temporal
dynamics pose challenges for RNA-sequencing experiments, as gene expression
patterns may vary across different time points or experimental conditions.
Longitudinal studies and time-series analyses are necessary to capture temporal
changes in gene expression and unravel regulatory networks underlying dynamic
biological processes. Biological samples are influenced by environmental
factors, experimental conditions, and technical artifacts that can introduce
variability and confound RNA-sequencing results. Sources of variation include
sample processing methods, RNA extraction protocols, library preparation
techniques, sequencing platforms, and computational pipelines. Controlling
environmental and experimental factors is essential for minimizing batch
effects, systematic biases, and false positives in RNA-sequencing experiments. Biological
samples may contain rare cell populations or subtypes with unique gene
expression profiles that are challenging to detect using bulk RNA-sequencing
approaches. Single-cell RNA-sequencing (scRNA-seq) technologies enable the
profiling of individual cells within heterogeneous populations, allowing
researchers to identify rare cell types, characterize cell-to-cell variability,
and dissect cellular heterogeneity at high resolution.
Key Market Trends
Increasing Adoption of NGS in
Transcriptomics
NGS-based
RNA-sequencing enables researchers to study gene expression patterns across the
entire transcriptome in a high-throughput and unbiased manner. Unlike
microarray-based methods, which are limited to the detection of predefined
probes, RNA-sequencing provides greater sensitivity and dynamic range for
detecting transcripts, alternative splicing events, and novel RNA isoforms. The
transcriptome is highly complex, consisting of coding and non-coding RNAs with
diverse functions and regulatory roles. NGS-based RNA-sequencing allows
researchers to profile gene expression at single-nucleotide resolution,
identify splice variants, quantify transcript abundance, and characterize RNA
modifications with high precision. This resolution enables the discovery of novel
transcripts, regulatory elements, and disease-associated biomarkers. NGS-based
RNA-sequencing is widely used across various research areas, including basic
biology, developmental biology, cancer biology, neuroscience, immunology, and
infectious diseases. Transcriptomic studies provide insights into gene
regulatory networks, cellular differentiation, disease mechanisms, drug
responses, and biomarker discovery, driving the adoption of RNA-sequencing
technologies in diverse scientific disciplines.
NGS-based
RNA-sequencing is often integrated with other omics data types, such as
genomics, epigenomics, proteomics, and metabolomics, to obtain a comprehensive
understanding of biological systems and disease processes. Integrated
multi-omics approaches enable researchers to correlate gene expression patterns
with genetic variations, epigenetic modifications, protein abundance, and
metabolic pathways, facilitating systems-level analyses and translational
research applications. NGS-based RNA-sequencing is increasingly used in
clinical research and diagnostics, particularly in the field of precision
medicine. Transcriptomic profiling of patient samples enables the
identification of disease-specific gene expression signatures, patient
stratification based on molecular subtypes, and prediction of treatment
responses. RNA-sequencing data also informs the development of targeted
therapies, biomarker-driven clinical trials, and personalized treatment
strategies for cancer and other complex diseases.
Segmental Insights
Technology Insights
The
Nanopore Sequencing segment is projected to experience rapid growth in the
Global NGS-Based RNA-Sequencing Market during the forecast period. Nanopore
sequencing technology offers the advantage of producing long read lengths,
which enables the direct sequencing of RNA molecules without the need for
fragmentation or amplification. Long-read RNA sequencing allows for the
characterization of full-length transcripts, including isoforms and splice variants,
providing valuable insights into RNA structure, function, and regulation.
Researchers and clinicians increasingly recognize the importance of long-read
sequencing in accurately capturing complex RNA landscapes, driving the demand
for nanopore sequencing platforms. One of the distinctive features of nanopore
sequencing is its ability to perform real-time, single-molecule sequencing.
This real-time capability allows researchers to observe RNA molecules as they
pass through nanopores, enabling dynamic monitoring of RNA modifications,
kinetics of RNA processing events, and RNA-protein interactions. Real-time
nanopore sequencing offers unprecedented insights into RNA biology and gene
expression dynamics, making it an attractive tool for a wide range of research
applications. Nanopore sequencing platforms, such as those offered by Oxford
Nanopore Technologies, are known for their portability and ease of use. These
compact, handheld devices enable RNA sequencing to be performed in various
settings, including fieldwork, point-of-care diagnostics, and resource-limited
environments. The accessibility and flexibility of nanopore sequencing systems
democratize RNA sequencing and empower researchers and clinicians worldwide to
conduct studies and diagnostics in diverse settings. Nanopore sequencing is
versatile and applicable to a wide range of RNA sequencing applications,
including transcriptome profiling, RNA modification analysis, RNA structural
characterization, and viral RNA detection. The versatility of nanopore
sequencing technology allows researchers to address diverse research questions
and explore RNA biology in unprecedented detail, fostering its widespread
adoption across academic, clinical, and industrial settings.
Download Free Sample Report
Regional Insights
North
America emerged as the dominant region in the Global NGS-Based RNA-Sequencing Market
in 2023. North America,
particularly the United States, is a leading hub for biomedical research and innovation.
The region is home to numerous prestigious universities, research institutions,
and biotechnology companies that actively invest in genomics and RNA sequencing
technologies. This concentration of expertise and resources fosters the
development and adoption of next-generation sequencing (NGS) techniques,
including RNA sequencing. North America boasts a robust biotechnology and
pharmaceutical industry, comprising both established companies and startups.
These organizations conduct extensive research and development (R&D) in
areas such as drug discovery, diagnostics, and personalized medicine, all of
which heavily rely on RNA sequencing technologies. The demand for NGS-based RNA
sequencing solutions is driven by the need to understand gene expression
patterns, identify therapeutic targets, and develop novel treatments for
diseases.
Recent Developments
- In
April 2023, IDT, a leading provider of genomics solutions worldwide, is aiding
research laboratories globally with a novel solution aimed at enhancing
operational efficiency and identifying solid cancer tumors. Recently launched,
the IDT Archer FUSIONPlex Core Solid Tumor Panel represents a cutting-edge
cancer research testing solution. This solution has been expanded and refined
to enhance coverage of single nucleotide variants (SNVs) and
insertions/deletions (indels), simplifying fusion detection and variant calling
through a unified assay. The newly introduced RNA-based sequencing solution for
solid tumors utilizes a single RNA/TNA input sample, presenting researchers
with a scalable, user-friendly option that saves time, resources, and costs.
Comprising a balanced pool of gene-specific primer (GSP) oligonucleotides
targeting 56 genes, the FUSIONPlex Core Solid Tumor Panel has been designed for
simplicity. The AMP-based library preparation for Archer NGS research assays
can be executed in just 1.5 days with minimal hands-on time.
Key Market Players
- Illumina
Inc.
- Thermo Fischer Scientific Inc.
- Oxford Nanopore Technologies plc
- Agilent Technologies, Inc.
- PerkinElmer Inc
- QIAGEN N.V.
- Eurofins Scientific SE
- F. Hoffmann-La Roche Ltd
- Takara Bio Inc.
- Azenta Life Sciences
|
By
Product and Services
|
By
Technology
|
By
Application
|
By
End- User
|
By
Region
|
- RNA
Sequencing Platforms and Consumables
- Sample
Preparation Products
- RNA
Sequencing Services
- Data
Analysis
- Storage
and Management
|
- Sequencing
by Synthesis
- Ion
Semiconductor Sequencing
- Single-Molecule
Real-Time Sequencing
- Nanopore
Sequencing
|
- Expression
Profiling Analysis
- Small
RNA Sequencing
- De
Novo Transcriptome Assembly
- Variant
Calling and Transcriptome Epigenetics
|
- Research
and Academia
- Hospitals
and Clinics
- Pharmaceutical
and Biotechnology Companies
- Others
|
- North
America
- Europe
- Asia-Pacific
- South
America
- Middle
East & Africa
|
Report Scope:
In this report, the Global NGS-Based RNA-Sequencing
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- NGS-Based RNA-Sequencing Market, By Product and Services:
o RNA
Sequencing Platforms and Consumables
o Sample Preparation Products
o RNA Sequencing Services
o Data Analysis
o Storage and Management
- NGS-Based RNA-Sequencing Market, By Technology:
o Sequencing by Synthesis
o Ion Semiconductor Sequencing
o Single-Molecule Real-Time Sequencing
o Nanopore Sequencing
- NGS-Based RNA-Sequencing Market, By Application:
o Expression Profiling
Analysis
o Small RNA Sequencing
o De Novo Transcriptome
Assembly
o Variant Calling and
Transcriptome Epigenetics
- NGS-Based RNA-Sequencing Market, By End User:
o Research and Academia
o Hospitals and Clinics
o Pharmaceutical and
Biotechnology Companies
o Others
NGS-Based RNA-Sequencing Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ Germany
§ United Kingdom
§ France
§ Italy
§ Spain
o Asia-Pacific
§ China
§ Japan
§ India
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global NGS-Based
RNA-Sequencing Market.
Available Customizations:
Global NGS-Based RNA-Sequencing market report
with the given market data, Tech Sci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global NGS-Based RNA-Sequencing Market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]